Cordatus Wealth Management’s AstraZeneca AZN Stock Holding History

Cordatus Wealth Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$364K	Buy	1,920 +141	+8%	+$26.5K	0.08%	133
2026 Q1	$351K	Buy	1,779 +95	+6%	+$18.3K	0.08%	128
2025 Q4	$310K	Sell	1,684 -175	-9%	-$30.7K	0.07%	138
2025 Q3	$285K	Buy	1,859 +39	+2%	+$5.9K	0.07%	140
2025 Q2	$254K	Sell	1,820 -73	-4%	-$10.2K	0.06%	151
2025 Q1	$278K	Buy	1,893 +332	+21%	+$48K	0.08%	134
2024 Q4	$205K	Buy	+1,561	New	+$219K	0.05%	143
2023 Q3	–	Sell	-3,298	Closed	-$472K	–	71
2023 Q2	$472K	Buy	+3,298	New	+$485K	0.18%	98
2022 Q3	–	Sell	-5,119	Closed	-$676K	–	73
2022 Q2	$676K	Buy	+5,119	New	+$672K	0.32%	102

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Cordatus Wealth Management's AZN Position: Q2 2026 in Review

Cordatus Wealth Management increased its AstraZeneca (AZN) stake by 7.9% in Q2 2026, buying an estimated $26.5K and bringing the position to 1,920 shares worth $364K. The position accounts for 0.08% of the portfolio, ranked #133.

Cordatus Wealth Management first reported a position in AZN in Q2 2022 and has held it in 9 quarters since. The position peaked at $676K in Q2 2022. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Cordatus Wealth Management held 1,920 shares of AstraZeneca worth $364K as of Q2 2026.
Cordatus Wealth Management bought 141 AstraZeneca shares in Q2 2026, an estimated $26.5K.
AstraZeneca made up 0.08% of Cordatus Wealth Management's portfolio in Q2 2026, its #133 holding.
Cordatus Wealth Management first reported a position in AstraZeneca in Q2 2022 and has held it in 9 quarters since.
Cordatus Wealth Management's AstraZeneca position peaked at $676K in Q2 2022.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Cordatus Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.